Pfizer secures up to $1.5 billion from Blackstone for obesity drug development
Blackstone will fund development costs through 2028 as Pfizer advances berobenatide, a monthly GLP-1 drug, in 10 Phase 3 trials.
7 Articles
7 Articles
Blackstone to provide Pfizer up to $1.5 billion through 2028 to support clinical program for GLP-1 receptor agonist - FINCHANNEL
NEW YORK & CAMBRIDGE, Mass.–Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences (“Blackstone”) today announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of $1.5 billion of development costs through 2028 for berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange f…
Blackstone Puts Up $1.5 Billion for Pfizer Obesity Drug Studies
Pfizer Inc. struck a deal with Blackstone Inc. to secure as much as $1.5 billion in funding to develop one of its experimental obesity drugs, giving the company additional capital as it races to compete in the booming weight-loss market.
Pfizer secures up to $1.5 billion from Blackstone for obesity drug development
Nov 11 (Reuters) - Pfizer said on Wednesday Blackstone would provide up to $1.5 billion through 2028 to help fund the development of its experimental monthly obesity treatment. (Reporting by Kunal Das in Bengaluru; Editing by Lero...
Portal GMC Online
O LiberalThe giant Pfizer fattened her chest to finance the development of berobenatide, a new experimental medicine of the agonist class...
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
